Pharmacological Therapy of Proliferative Vitreoretinopathy: Systematic In Vitro Comparison of 36 Pharmacological Agents
Journal of Ocular Pharmacology and Therapeutics · 2023
DOI: 10.1089/jop.2022.0078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, 2023. Verfasst von Natalie Tersi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Vitreoretinopathy, Proliferative. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Purpose
Proliferative vitreoretinopathy (PVR) is currently treated surgically. Reliable pharmaceutical options would be desirable, and numerous drugs have been proposed. This in vitro study is intended to systematically compare and determine the most promising candidates for the treatment of PVR.
Methods
A structured literature review was conducted in the "PubMed" database to identify previously published agents proposed for medical treatment of PVR -36 substances that met the inclusion criteria. Toxicity and antiproliferative effects were evaluated on primary human retinal pigment epithelial (hRPE) using colorimetric viability assays. The seven substances with the widest therapeutic range between toxicity and no longer detectable antiproliferative effect were then validated with a bromodeoxyuridine assay and a scratch wound healing assay using primary cells derived from surgically excised human PVR membranes (hPVR).
Results
Among 36 substances, 12 showed no effect on hRPE at all. Seventeen substances had a significant (P < 0.05) toxic effect of which nine did not have an antiproliferative effect. Fifteen substances significantly reduced hRPE proliferation (P < 0.05). The seven most promising drugs with the highest difference between toxicity and antiproliferative effects on hRPE were dasatinib, methotrexate, resveratrol, retinoic acid, simvastatin, tacrolimus, and tranilast. Whereof resveratrol, simvastatin, and tranilast additionally showed antiproliferative and dasatinib, resveratrol, and tranilast antimigratory effects on hPVR (P < 0.05).
Conclusion
This study presents a systematic comparison of drugs that have been proposed for PVR treatment in a human disease model. Dasatinib, resveratrol, simvastatin, and tranilast seem to be promising and are well-characterized in human use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology and University Hospital, LMU Munich, Munich, Germany.
- Department of Ophthalmology, University Hospital, Ulm University, Ulm, Germany.
- Department of Dermatology and Allergology, University Hospital, LMU Munich, Munich, Germany.
Zitieren
APA
Tersi, N., Kassumeh, S., Ohlmann, A., Strehle, L., Priglinger, S. G., Hartmann, D., Wolf, A., & Wertheimer, C. M. (2023). Pharmacological Therapy of Proliferative Vitreoretinopathy: Systematic In Vitro Comparison of 36 Pharmacological Agents. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2022.0078
Vancouver
Tersi N, Kassumeh S, Ohlmann A, Strehle L, Priglinger SG, Hartmann D, et al. Pharmacological Therapy of Proliferative Vitreoretinopathy: Systematic In Vitro Comparison of 36 Pharmacological Agents. Journal of Ocular Pharmacology and Therapeutics. 2023. doi:10.1089/jop.2022.0078
BibTeX
@article{Tersi2023,
author = {Tersi, Natalie and Kassumeh, Stefan and Ohlmann, Andreas and Strehle, Laura and Priglinger, Siegfried G and Hartmann, Daniela and Wolf, Armin and Wertheimer, Christian M},
title = {Pharmacological Therapy of Proliferative Vitreoretinopathy: Systematic In Vitro Comparison of 36 Pharmacological Agents},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2023},
doi = {10.1089/jop.2022.0078}
}
EUVIMED